Dentons US LLP
Methods for assessing and identifying or evolving conditionally active therapeutic proteins
Methods for evolving or selecting or producing therapeutic proteins that exhibit reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein.
Halozyme, Inc.
C G G G C G A G C C
C07K G01N G01N G01N C07K G01N A61P G01N C07K C07K
inventional inventional additional inventional inventional inventional inventional inventional inventional additional
Ge Louis H. Harold Michael Gregory I. Philip Lee Lei Lalitha
Wei Bookbinder Shepard Frost Sheridan Huang Kodandapani